Clinical MomentumRecent clinical and commercial momentum within key markets, including the US, Europe, and Japan, indicates increasing awareness and adoption of ProSense for the treatment of breast cancer and other indications.
Market PotentialThe ProSense cryoablation procedure, which is minimally invasive, has the potential to replace lumpectomy for the target patient population of approximately 46,000 women in the U.S. annually.
Regulatory ProgressAnalyst is bullish on the advancements ICCM has made on pursuing De Novo marketing authorization from the FDA for early stage, low-risk breast cancer.